IGM BIOSCIENCES INC (IGMS)       24  -1.4 (-5.51%)

24  -1.4 (-5.51%)

US4495851085 - Common Stock - After market: 24 0 (0%)

IGM BIOSCIENCES INC24

NASDAQ:IGMS (2/3/2023, 7:00:03 PM)-1.4 (-5.51%)

After market: 24 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-03 2022-11-03/bmo Earnings (Next) 03-27 2023-03-27/amc
Ins Owners 0.76% Inst Owners 41.29%
Market Cap 1.03B Shares 42.83M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 84.71
IPO 09-18 2019-09-18

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

IGMS Daily chart

Company Profile

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 242 full-time employees. The company went IPO on 2019-09-18. The firm has created an IgM antibody technology platform for developing T cell engagers, receptor cross-linking agonists, targeted cytokines and target neutralizers. Its product candidates in clinical testing include IGM-2323 and IGM-8444. IGM-2323 is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in a Phase II clinical trial for the treatment of relapsed/refractory B cell non-Hodgkins lymphoma (NHL) patients. IGM-8444 is an IgM antibody targeting Death Receptor 5 (DR5) proteins for the treatment of patients with solid and hematologic malignancies, is in a Phase I clinical trial for the treatment of solid cancers. Its oncology pipeline also includes IGM-7354, IGM-2644 and IGM-2537.

Company Info

IGM BIOSCIENCES INC

325 E Middlefield Rd

Mountain View CALIFORNIA 94043

P: 16509657873.0

CEO: Fred Schwarzer

Employees: 242

Website: https://igmbio.com/

IGMS News

News Image3 days ago - IGM Biosciences, Inc.IGM Biosciences to Present at the Guggenheim 2023 Oncology ConferenceNews Image3 days ago - IGM Biosciences, Inc.IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference

MOUNTAIN VIEW, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating...

News Image19 days ago - IGM Biosciences, Inc.IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors

– Targeted IL-15/IL-15R IgM antibody to be evaluated for safety and pharmacodynamic effects –

News Image21 days ago - MedivirMedivir to present at the Redeye Fight Cancer Day

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

News Image25 days ago - Market News VideoIGM Biosciences (IGMS) Shares Cross Above 200 DMANews Imagea month ago - IGM Biosciences, Inc.IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

IGMS Twits

Here you can normally see the latest stock twits on IGMS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example